Clinical characteristics of 109 patients randomized in the 2 trials
| . | Trial 1 . | Trial 2 . | ||||
|---|---|---|---|---|---|---|
| No ATG . | ATG 7.5 (mg/kg) . | P . | No ATG . | ATG 15 (mg/kg) . | P . | |
| No. of patients | 25 | 29 | 28 | 27 | ||
| Donor age (y) | 38 | 35 | .2 | 37 | 36 | .7 |
| CMV+ | 48% | 55% | .6 | 46% | 51% | .9 |
| Recipient age (y) | 29 | 28 | .7 | 28 | 32 | .2 |
| (range) | (13-51) | (18-48) | (14-46) | (14-52) | ||
| CMV+ | 72% | 79% | .5 | 62% | 74% | .2 |
| Interval Dx-BMT (d) | 713 | 871 | .03 | 547 | 608 | .7 |
| Disease 1st CR/CP | 60% | 62% | .8 | 36% | 22% | .2 |
| Number cells × 108/kg | 3.4 | 3 | .2 | 3.6 | 3.3 | .3 |
| (range) | (1.2-7.8) | (1.4-13) | (1.6-7.6) | (0.8-6.5) | ||
| . | Trial 1 . | Trial 2 . | ||||
|---|---|---|---|---|---|---|
| No ATG . | ATG 7.5 (mg/kg) . | P . | No ATG . | ATG 15 (mg/kg) . | P . | |
| No. of patients | 25 | 29 | 28 | 27 | ||
| Donor age (y) | 38 | 35 | .2 | 37 | 36 | .7 |
| CMV+ | 48% | 55% | .6 | 46% | 51% | .9 |
| Recipient age (y) | 29 | 28 | .7 | 28 | 32 | .2 |
| (range) | (13-51) | (18-48) | (14-46) | (14-52) | ||
| CMV+ | 72% | 79% | .5 | 62% | 74% | .2 |
| Interval Dx-BMT (d) | 713 | 871 | .03 | 547 | 608 | .7 |
| Disease 1st CR/CP | 60% | 62% | .8 | 36% | 22% | .2 |
| Number cells × 108/kg | 3.4 | 3 | .2 | 3.6 | 3.3 | .3 |
| (range) | (1.2-7.8) | (1.4-13) | (1.6-7.6) | (0.8-6.5) | ||
Dx-BMT, interval diagnosis transplant; 1st CR/CP, first remission or chronic phase.
P < .05.